Question 1

What is Namodenoson?

Accepted Answer

Namodenoson is a Other.

Question 2

How often does Namodenoson appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Namodenoson first tracked by Ergen?

Accepted Answer

First tracked on Jul 01, 2026.

Question 4

When was Namodenoson last mentioned in news?

Accepted Answer

Last active on Jul 01, 2026.

Question 5

What is Namodenoson's current news sentiment?

Accepted Answer

Aggregate sentiment score: 65 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Namodenoson in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Namodenoson?

Accepted Answer

Can-Fite Namodenoson Pancreatic Cancer Study (Jul 01, 2026, 6 articles).

Question 8

How did the "Can-Fite Namodenoson Pancreatic Cancer Study" event impact Namodenoson?

Accepted Answer

Namodenoson, a drug developed by Can-Fite BioPharma Ltd., showed durable survival outcomes and a favorable safety profile in a Phase 2a study for advanced pancreatic cancer, leading to plans for further clinical development in combination with chemotherapy.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.